ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Travoprost

Also written as “Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)”, “Travoprost 0.004% / Timolol maleate 0.5%” and “Travoprost 0.004% ophthalmic solution”.

Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Glaucoma, Angle-Closure · Low Tension Glaucoma · Hydrophthalmos, led by 5 companies.

Drug pageTravoprost: every studyMany companies study it; this page follows only the 63 they lead. All 80 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 28, 200363 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alconits history only520 open or runningphase 4since May 28, 2003Jan 3, 2003none ahead
Glaukos72 open or runningphase 4since Sep 28, 2011Sep 28, 2011none ahead
Ocular Therapeutixits history only20 open or runningphase 3since Sep 21, 2016Dec 4, 2014none ahead
Laboratorios Sophia S.A de C.V.its history only10 open or runningphase 1since May 23, 2019May 23, 2019none ahead
Viatrisits history only10 open or runningphase 4since Feb 16, 2009Feb 16, 2009none ahead

Also a collaborator on its studies: PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Glaukos only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2011First studies: 2 phase 4 studies in Glaucoma, Open-AngleFirst studyNCT01444040, NCT01443988
  2. Aug 11, 2016Phase 4 study in Glaucoma, Open-AngleNCT02873806 · 53 enrolled · Armenia
  3. Oct 29, 2020Phase 2 study in Glaucoma, Open-AngleNCT04615403 · 33 enrolled · United States, Philippines
  4. Sep 25, 2023Phase 3 study in Glaucoma, Open-AngleNCT06061718 · 60 enrolled · Armenia
  5. Aug 30, 2024Phase 2 study in Glaucoma, Open-AngleNCT06582732 · 210 enrolled · Armenia
  6. Feb 1, 2025Phase 4 study in Glaucoma, Open-AngleNCT06848946 · 132 planned · United States

TargetBeta

PTGFR →read by rule
“Prostanoid FP receptor agonist”ChEMBL 37, by rule

Other programs on PTGFR

ProgramCompanyFurthest phaseStudies
AGN-193408AbbViephase 21

Studies

All 7 Glaukos leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06848946Glaucoma, Open-Angle · United States4RecruitingAug 2026132
NCT06582732Glaucoma, Open-Angle · Armenia2CompletedNov 2, 2023210
NCT06061718Glaucoma, Open-Angle · Armenia3Active, not recruitingMar 18, 202460
NCT04615403Glaucoma, Open-Angle · United States, Philippines2CompletedFeb 28, 202233
NCT02873806Glaucoma, Open-Angle · Armenia4CompletedNov 8, 201953
NCT01444040Glaucoma, Open-Angle · Armenia4CompletedMar 28, 2019196
NCT01443988Glaucoma, Open-Angle · Armenia4CompletedJan 2017101

How it is read

Names in the registry

  • “Travoprost”, 6 entries
  • “Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)”, 5 entries
  • “Travoprost 0.004% / Timolol maleate 0.5%”, 2 entries
  • “Travoprost 0.004% ophthalmic solution”, 2 entries
  • “Travoprost ophthalmic solution, 0.004%”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.